AbbVie announced key results from a phase 2 study of upadacitinib given as monotherapy, or in combination therapy (ABBV-599) with elsubrutinib, a kinase inhibitor...
AbbVie announced topline results from a Phase 2 study of upadacitinib given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib,...
Nektar Therapeutics announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of rezpegaldesleukin in adults with moderately-to-severely active systemic lupus erythematosus (SLE)...
